First drug approved in 2021

Poxel is developing a pipeline of several mid-to-late-stage drug candidates targeting the mitochondrial dysfunction. Imeglimin was approved as TWYMEEG^® for type 2 diabetes in Japan in June 2021 and was launched in September 2021. Imeglimin has also successfully completed Phase 2 development in the U.S. and EU. PXL770 and PXL065 are in mid-stage development for NASH. We are also evaluating our AMPK activation and TZD platforms for other chronic and rare metabolic diseases with the objective to launch Phase 2a proof-of-concept studies in ALD early 2022.